Viemed Healthcare (NASDAQ: VMD) is one of 27 public companies in the “Miscellaneous health & allied services, not elsewhere classified” industry, but how does it weigh in compared to its competitors? We will compare Viemed Healthcare to related businesses based on the strength of its institutional ownership, risk, valuation, dividends, analyst recommendations, profitability and earnings.
Risk & Volatility
Viemed Healthcare has a beta of 1.44, suggesting that its stock price is 44% more volatile than the S&P 500. Comparatively, Viemed Healthcare’s competitors have a beta of 7.07, suggesting that their average stock price is 607% more volatile than the S&P 500.
This table compares Viemed Healthcare and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Viemed Healthcare Competitors||-39.15%||16.05%||-9.95%|
Valuation and Earnings
This table compares Viemed Healthcare and its competitors top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Viemed Healthcare||$131.31 million||$31.53 million||9.50|
|Viemed Healthcare Competitors||$1.94 billion||$96.17 million||42.51|
Viemed Healthcare’s competitors have higher revenue and earnings than Viemed Healthcare. Viemed Healthcare is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Institutional & Insider Ownership
51.1% of Viemed Healthcare shares are owned by institutional investors. Comparatively, 43.2% of shares of all “Miscellaneous health & allied services, not elsewhere classified” companies are owned by institutional investors. 26.4% of shares of all “Miscellaneous health & allied services, not elsewhere classified” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
This is a summary of recent recommendations and price targets for Viemed Healthcare and its competitors, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Viemed Healthcare Competitors||92||389||535||15||2.46|
Viemed Healthcare presently has a consensus target price of $12.50, suggesting a potential upside of 68.69%. As a group, “Miscellaneous health & allied services, not elsewhere classified” companies have a potential upside of 6.06%. Given Viemed Healthcare’s stronger consensus rating and higher possible upside, equities analysts plainly believe Viemed Healthcare is more favorable than its competitors.
Viemed Healthcare beats its competitors on 7 of the 13 factors compared.
Viemed Healthcare Company Profile
Viemed Healthcare, Inc., through its subsidiaries, provides in-home durable medical equipment and post-acute respiratory healthcare services to patients in the United States. The company offers respiratory services and related equipment, including non-invasive ventilators; bi-level, continuous, and automatic continuous positive airway pressure (PAP) machines; and oxygen therapy, as well as services of respiratory therapists; and respiratory disease management, neuromuscular care, and oxygen therapy services. It also provides in-home sleep apnea testing services to determine the existence of sleep apnea at home. In addition, the company leases non-invasive and invasive ventilators, PAP machines, percussion vests, oxygen concentrator units, and other respiratory equipment, as well as sells medical equipment and/or patient medical services. Further, it provides therapy and counseling to patients in their homes using its technology. The company was founded in 2006 and is headquartered in Lafayette, Louisiana.
Receive News & Ratings for Viemed Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viemed Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.